10X Genomics says Bio-Rad can't avoid US antitrust counterclaims
MLex Summary: 10X Genomics told a US judge that it has presented ample evidence of Bio-Rad Laboratories’ illegal monopolization of multiple markets relating to genetic analysis, and 10X's claims shouldn't be...To view the full article, register now.
Already a subscriber? Click here to view full article